ArticlePharmaceutics2019
Investigation of Fugitive Aerosols Released into the Environment during High-Flow Therapy.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.Journal of aerosol medicine and pulmonary drug delivery · 2020Guideline
- From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy.Asian journal of pharmaceutical sciences · 2024Review
- Article
- Characterization of SARS-CoV-2 Aerosols Dispersed During Noninvasive Respiratory Support of Patients With COVID-19.Respiratory care · 2023Article
- Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control.Drug delivery · 2022Article
- Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen.ERJ open research · 2022Article
- The Impact of Head Model Choice on the In Vitro Evaluation of Aerosol Drug Delivery.Pharmaceutics · 2021Article
- AnDrug delivery · 2021Article
- Electrochemical Discrimination of Salbutamol from Its Excipients in VentolinSensors (Basel, Switzerland) · 2021Article
- Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis.Antibiotics (Basel, Switzerland) · 2021Article
- Fugitive aerosols in the intensive care unit: a narrative review.Annals of translational medicine · 2021Review
- Guidance for nebulization during the COVID-19 pandemic.Lung India : official organ of Indian Chest Society · 2021Article
- Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation.Pharmaceutics · 2021Article
- How to deliver aerosolized medications through high flow nasal cannula safely and effectively in the era of COVID-19 and beyond: A narrative review.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2021Review
- Guidance on nebulization during the current COVID-19 pandemic.Respiratory medicine · 2021Review
- Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home.International journal of chronic obstructive pulmonary disease · 2021Review
- Procedures in COVID-19 Patients: Part-I.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Review
- Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.Pharmaceutics · 2020Review
- Advances in Pulmonary Drug Delivery.Pharmaceutics · 2020Article
- A narrative review on trans-nasal pulmonary aerosol delivery.Critical care (London, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNebulised medical aerosols are designed to deliver drugs to the lungs to aid in the treatment of respiratory diseases. However, an unintended consequence is the potential for fugitive emissions during patient treatment, which may pose a risk factor in both clinical and homecare settings.
methodsThe current study examined the potential for fugitive emissions, using albuterol sulphate as a tracer aerosol during high-flow therapy. A nasal cannula was connected to a head model or alternatively, a interface was connected to a tracheostomy tube in combination with a simulated adult and paediatric breathing profile. Two aerodynamic particle sizers (APS) recorded time-series aerosol concentrations and size distributions at two different distances relative to the simulated patient.
resultsThe results showed that the quantity and characteristics of the fugitive emissions were influenced by the interface type, patient type and supplemental gas-flow rate. There was a trend in the adult scenarios; as the flow rate increased, the fugitive emissions and the mass median aerodynamic diameter (MMAD) of the aerosol both decreased. The fugitive emissions were comparable when using the adult breathing profiles for the nasal cannula and tracheostomy interfaces; however, there was a noticeable distinction between the two interfaces when compared for the paediatric breathing profiles. The highest recorded aerosol concentration was 0.370 ± 0.046 mg m
conclusionsOverall, the results highlight the potential for secondary inhalation of fugitive emissions released during simulated aerosol treatment with concurrent high-flow therapy. The findings will help in developing policy and best practice for risk mitigation from fugitive emissions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.